Durable Regression of Primary Cutaneous B-Cell Lymphoma Following Fever-inducing Mistletoe Treatment: Two Case Reports

dc.contributor.authorOrange, Maurice
dc.date.accessioned2024-05-23T18:54:22Z
dc.date.available2024-05-23T18:54:22Z
dc.date.digitized2021-03-14 20:43:01
dc.date.issued2012
dc.description.abstract<p><strong>Abstract</strong><br /><strong>Background</strong>: Mistletoe is a complementary cancer treatment that is widely used, usually in addition to and alongside recommended conventional cancer therapy. However, little is known about its use, effectiveness, and safety in the treatment of cutaneous lymphoma. <strong>Case Report</strong>: Two patients with primary cutaneous B-cell lymphoma (pT2bcNxM0 follicle center and pT2ac-NxM0 marginal zone) either declined or postponed recommended conventional treatment and received highdose, fever-inducing mistletoe treatment; a combination of intratumoral, subcutaneous, and intravenous application was given; and one patient also underwent whole-body hyperthermia. The lymphoma regressed over a period of 12 and 8 months, respectively, and after administration of a cumulative dose of 12.98 g and 4.63 g mistletoe extract, respectively. The patients are in remission to date, 3.5 years after commencement of treatment. Neither patient received conventional cancer treatment during the entire observation period.</p> <p><strong>Citation</strong>: Orange, M., Lace, A., Fonseca, M. P., Von Laue, B. H., Geider, S., &amp; Kienle, G. S. (2012). Durable Regression of Primary Cutaneous B-Cell Lymphoma following Fever-inducing Mistletoe Treatment: Two Case Reports. <em>Global Advances in Health and Medicine</em>, <em>1</em>(1), 18–25. <a href="https://doi.org/10.7453/gahmj.2012.1.1.006" target="_blank">https://doi.org/10.7453/gahmj.2012.1.1.006</a></p>
dc.identifier.citationOrange, M., Lace, A., Fonseca, M. P., Von Laue, B. H., Geider, S., & Kienle, G. S. (2012). Durable Regression of Primary Cutaneous B-Cell Lymphoma following Fever-inducing Mistletoe Treatment: Two Case Reports. Global Advances in Health and Medicine, 1(1), 18–25. https://doi.org/10.7453/gahmj.2012.1.1.006
dc.identifier.doihttps://doi.org/10.7453/gahmj.2012.1.1.006
dc.identifier.externalUrl/library/2021/3/8/durable-regression-of-primary-cutaneous-b-cell-lymphoma-following-fever-inducing-mistletoe-treatment-two-case-reports
dc.identifier.urihttps://hdl.handle.net/20.500.14430/437
dc.subject.otherLymphoma
dc.subject.otherprimary cutaneous B-cell lymphoma
dc.subject.otherPCBCL
dc.subject.otherPCFCL
dc.subject.otherPCMZL
dc.subject.othertumor
dc.subject.otherFever
dc.subject.otherMistletoe treatment
dc.subject.otherCancer
dc.titleDurable Regression of Primary Cutaneous B-Cell Lymphoma Following Fever-inducing Mistletoe Treatment: Two Case Reports
dspace.entity.typePublication
oaire.citation.titleGlob Advances Health Med
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Orange_durable Regression of primary Cutaneous b-cell lymphoma_2012.pdf
Size:
1.48 MB
Format:
Adobe Portable Document Format